Clinical Trials Logo

Filter by:
NCT ID: NCT05020015 Active, not recruiting - Clinical trials for Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Start date: November 12, 2021
Phase: Phase 2
Study type: Interventional

This study has 2 parts. The main aim of Part 1 is to check for side effects from TAK-007 in adults with relapsed or refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL), The main aim of Part 2 is to learn whether lymphoma disease responds to treatment with TAK-007 in adults with r/r B-cell NHL or iNHL. Participants will receive 3 days of chemotherapy to reduce a type of white blood cells called lymphocytes, in the blood. This is called lymphodepleting chemotherapy (LDC) or lymphodepletion. After LDC, patients will receive a single injection of TAK-007 or three weekly injections of TAK-007 (multi-dose injection). After this, participants will regularly visit the clinic for check-ups.

NCT ID: NCT05019521 Active, not recruiting - Geographic Atrophy Clinical Trials

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Start date: August 23, 2021
Phase: Phase 2
Study type: Interventional

This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.

NCT ID: NCT05018897 Active, not recruiting - Mood Disorders Clinical Trials

Strategic Disclosure Intervention for Suicide Attempt Survivors

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

While suicide prevention depends on people disclosing suicidal thoughts and behaviors in order to get help, those who talk about their suicidality also face negative responses from the people who they tell. The investigators will conduct a randomized controlled trial of a peer-led strategic disclosure intervention for suicide attempt survivors (The To Share or Not to Share Program; called 2Share). This study evaluates the impact of the intervention on suicidal thoughts and behaviors, depression, stigma, disclosure behaviors, and psychosocial outcomes.

NCT ID: NCT05018650 Active, not recruiting - Clinical trials for Acute Ischemic Stroke

A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)

Start date: December 21, 2021
Phase: N/A
Study type: Interventional

The SUMMIT MAX study is a prospective, randomized, controlled, interventional clinical trial to evaluate the safety and effectiveness of the Route 92 Medical MonoPoint® Reperfusion System with the Hi Point 88 and HiPoint 70 Reperfusion Catheters for aspiration thrombectomy in acute ischemic stroke patients.

NCT ID: NCT05018416 Active, not recruiting - Clinical trials for Type 2 Diabetes Mellitus

Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

Start date: July 27, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, efficacy, and durability of up to two REACT injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys on renal function progression in two different cohorts of subjects with T1DM or T2DM and CKD.

NCT ID: NCT05018286 Active, not recruiting - Clinical trials for Short Bowel Syndrome

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

STARS extend
Start date: July 13, 2021
Phase: Phase 3
Study type: Interventional

The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.

NCT ID: NCT05018273 Active, not recruiting - Solid Tumors, Adult Clinical Trials

Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

Start date: December 21, 2021
Phase: Phase 1
Study type: Interventional

A phase 1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, antigen-specific immune response and preliminary antitumor activity associated with VB10.NEO administered in combination with atezolizumab, and to identify a RP2D for VB10.NEO in combination with atezolizumab, in patients with locally advanced and metastatic tumors that have progressed after at least 1 available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable, or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care (SOC).

NCT ID: NCT05018143 Active, not recruiting - Suicide Clinical Trials

Suicide Prevention Intervention for Vulnerable Emerging Adult Sexual Minorities

Start date: October 20, 2022
Phase: N/A
Study type: Interventional

Emerging adult sexual minorities (EASM) are vulnerable to stressors that increase risk for suicidal ideation and behaviors. The investigators will examine a mobile application that leverages skills coaching and peer mentoring to reduce suicide risk for EASM. The online life skills intervention (iREACH) was developed to reduce a variety of negative health outcomes using telehealth with peer mentors. In Supporting Transitions to Adulthood and Reducing Suicide (STARS), investigators' interdisciplinary team will adapt iREACH to reduce suicidal ideation and behaviors among EASM. Then, investigators will pilot test STARS using in a racially/ethnically diverse sample of EASM with suicidal ideation. Participants will be randomized to receive an in-person brief, evidence-based safety planning protocol or to receive safety planning plus access to STARS. This project will identify the potential clinical utility of STARS for suicide prevention in a vulnerable, marginalized, population to inform a future larger efficacy RCT.

NCT ID: NCT05018091 Active, not recruiting - Clinical trials for Total Knee Arthroplasty

Dexamethasone in Total Knee Arthroplasty

Start date: October 28, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the most efficacious and safest dexamethasone dose given intraoperatively during total knee arthroplasty that reduces postoperative opioid consumption and pain, improves postoperative nausea and vomiting, and minimizes postoperative complications.

NCT ID: NCT05018000 Active, not recruiting - Cancer Clinical Trials

Cancer Financial Experience

CAFE
Start date: August 11, 2021
Phase: N/A
Study type: Interventional

This study is a randomized clinical trial designed to test a novel financial navigation intervention. The study assesses the impact of the financial navigation intervention on financial hardship and health-related quality of life, cancer-related material and psychological financial hardship, patient-centered communication, and time to initiation of treatment.